FARMINGTON, Conn., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Immuron Limited: According to AAA research released this week, 48.7 million Americans are expected to travel within the U.S. this Thanksgiving. Many will unfortunately get sick, or experience intestinal discomfort, from the food they eat.
And, while most people associate improper sanitation of food and water during international travel with E. coli-based illnesses, last year’s largest ongoing E. coli outbreak was actually in the United States, and took place at several Chipotle restaurants. So it’s important to be prepared when you stop for a quick bite to eat as you travel for your holiday celebrations.
Travelan was developed by Australian bio-pharmaceutical company Immuron Limited to help protect your intestinal track against the 13 most common strains of E. coli*. Popular in its native Australia for the past 10 years, and in Canada for the past three years, Travelan is now available in the United States on CVS.com and in select CVS/pharmacy stores, on Amazon.com, at Passport Health clinics and other travel medical providers.
About Immuron Limited:
Immuron Limited™ is a publicly listed Australian bio-pharmaceutical company (ASX:IMC) focused on oral immunotherapy using polyclonal antibody products. Immuron is a uniquely positioned company developing therapeutic products in NASH (fatty-liver disease), ASH (alcoholic fatty-liver disease) and other diseases mediated through gut dysbiosis.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.GlobeNewswire
Last updated on: 22/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.